XXXXXXXX KOMISE X XXXXXXXXX XXXXXXXXX (XX) x. 1062/2014
xx dne 4. xxxxx 2014,
týkající se xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx všech xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx, které xxxx xxxxxxx x xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) x. 528/2012
(Xxxx x xxxxxxxx xxx XXX)
XXXXXXXX XXXXXX,
x xxxxxxx xx Xxxxxxx x xxxxxxxxx Evropské xxxx,
x xxxxxxx na xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) x. 528/2012 ze xxx 22. xxxxxx 2012 x xxxxxxxx xxxxxxxxxx xxxxxxxxx na xxx a xxxxxx xxxxxxxxx (1), x xxxxxxx xx xx. 89 xxxx. 1 xxxxx xxxxxxxxxxx xxxxxxxxx nařízení,
vzhledem x xxxxx xxxxxxx:
(1) |
Xxxxxxxx Xxxxxx (XX) x. 1451/2007 (2) xxxxxxx xxxxxxxxx pravidla xxx xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxx (dále jen „xxxxxxx xxxxxxxx“), xxxxx xxx xxxxxxx x xxxxxxx x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX (3). Xxxxxxx tato xxxxxxxx byla xxxxxxx x xxxxxxxxx xxxxxxxxx (EU) x. 528/2012, měla xx xxx prováděcí pravidla xxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx nařízení. |
(2) |
Xx xxxxxxxx xxxxx kombinace účinné xxxxx x xxxx xxxxxxxxx, xxxxx xxxxx xxx dodávány na trh x xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxx 89 xxxxxxxx (XX) x. 528/2012 x xxxxxxxx xxxxxxxxxxxxxx předpisů. Xxxx xx xxxx xxx x v případě xxxxxxxxx účinné xxxxx x xxxx přípravku, xxxxx xxxx xxxxxxxxx x programu přezkumu. |
(3) |
Xxxxx xxxxxxxxx xxxxxxxx odchylky xxx xxxxxxxxx x xxxxxx xxxxx xxxxxx 6 xxxxxxxx (XX) x. 1451/2007, xxx xxxxxxxxxx se xx něj xxxxxxx xxx potraviny a krmiva xxxxxxx x xx. 2 xxxx. 5 xxxx. x) xxxxxxxx (EU) x. 528/2012, xxxx by xxx xxxxxx látky, xxxxx xxxxxxxx, hodnoceny x xxxxxxxx přezkumu pro xxxxxxxxx typ přípravku. X xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxx xxxxxxxx xx xxx x xxxxxxxxx umožněno až xx xxxxxxxx xxxxxxxxx hodnocení. Xxxxxx předchozího prohlášení xx xxx xxxxxxx, xxxxx xxxxxxxxx tohoto xxxxxxxxxx využijí. Totéž xx xxxx platit x xxxxxxxxx, kdy neoznámení xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx x xxxx definice xxxx xxxxxxxxx v nařízení (XX) x. 528/2012 oproti xxxxxxxx xxxxxxx xx xxxxxxxx 98/8/XX xxxx xx xxxxx xxxxxxxxxx xxxxxxxxxxx Komise přijatým x xxxxxxx x xx. 3 xxxx. 3 xxxxxxxx (EU) x. 528/2012, xxxxxxxxxxx (například xxxxxxxxxxx xx xxxx X-420/10 (4)) xxxx xxxxxxxxx pokyny Xxxxxx či xxxxxxxxxxx xxxxxx členských států, xxxxx se xxxxxxxx xxxxxxx. |
(4) |
Xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx účinnou xxxxx, xxxxx již xxxx xxxxxxxx xx xxxxxxxx xxxxxxxx, x této xxxxx xxxxxxx xxxx xx x xx xxxxxx, xxxxx xxxxxxxx xx používání tohoto xxxxxxxxxx xxxxxxxxx v členském xxxxx nezbytné, xxxx xx xxx x xxxxx xxxxxxxx xxxxx xxxxxxx x dodávání xx xxx xxxxxxxx xx xxxx xxxxxxxxxxxx, za určitých xxxxxxxx x xx omezenou xxxx. |
(5) |
X zájmu xxxxxxxxxxx x xxxxxxxxxxxx xx xxx xxx xxxxxx xxxxxxxxx xxxxxxxx látek x xxxxxxxx xxxxxxxx xx xxxxx xxxxxxxxxx xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxx xxxxxx 7 xxxxxxxx (XX) x. 528/2012 nebo xxxxx prováděcího xxxxxxxx Xxxxxx (EU) x. 88/2014 (5). |
(6) |
Xxx xxxxx, které xxxxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxxx xxx náhradu, xx xxx xxxxxxxxx xxxxxxxxx orgán xxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxx xxxxx čl. 37 xxxx. 1 xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (ES) x. 1272/2008 (6), xxxxx xxx o xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx, a zároveň xx xxxx být xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx týkající xx jiných nebo xxxxx sledovaných vlastností. Xxxxxxxxx xxxxxxxxx xxxxx xx xxx xxxx xxxxxxxxxxx xxxxxxxx x xxxxxxx látek, xxxxx xx splňovaly xxxxxxxx xxx látky perzistentní, xxxxxxxxxxxxxxx či toxické, xxxx xxxxx, xxxxx xx xxxxx být xxxxxxxxxx xx xxxxx x xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx. |
(7) |
Xxx bylo xxxxxxxxx, xx xxxxxxx xxxxxxxx xxxx xxxxxxxx do xxxxxxxx xxxx xxxxxxxxx x xx. 89 xxxx. 1 xxxxxxxx (XX) x. 528/2012, mělo xx xx xxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxx xxxxx a typu xxxxxxxxx, x xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx x xxxxxxxx (ES) x. 1451/2007 xxxx x xxxxx xxxxxxxx. Xxxxx toho xx xx měly xxxxxxxx xxxxxx lhůty pro xxxxxxxxx hodnocení, xxxxxxx xx se měla xxxx x xxxxx xxxxxxx, xx žádosti xx xxxxx xxx xxxxxxxxx xxxx než xxx před xxxxxxxxx xxxxxx xxxx. |
(8) |
Xxxxxxx xxxxxxxx xx xxxxxxx I xxxxxxxxx 7 nařízení (XX) x. 528/2012 dosud xxxxxx stanoveny xxxxx xxxxxxxxx na údaje. Xx xxxxx vhodné x této xxxx xxxxxx žádosti x xxxxxxxx xx uvedené xxxxxxx xx kategorie 1, 2, 3, 4, 5 nebo 6. |
(9) |
Xxx xxxxxx xx xx. 90 xxxx. 2 xxxxxxxx (EU) x. 528/2012 xxxxxxx x xxxxxx 91 xxxxxxxxx nařízení, že xxxxxxxx xxxxxxx v článku 10 xxxxxxxxx xxxxxxxx xx xxxx xxx relevantní xxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxx xxxxxxxxx. Je xxxxx xxxxxx xxxxx xxxxx xxxxxxxxx xxxx kritéria xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx. |
(10) |
Xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx by xxx xxx xxxxxxx xx xx vzájemné xxxxxx xxxxxxxx ke xxxxxxxxxxx xxxxxxxxxxx xxxx jej xxxxxxxx za xxxxxxxxxxx, xx xxxxx tomu xxxxxxx xx xxxxxxxx xxxxxxxxx z důvodu omezeného xxxxxxxx x xxxxxx, xxxxxxx jinak xx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxx. |
(11) |
Protože xx xxxxx v programu xxxxxxxx xxxxxxxxxx, mělo xx xxx xxxxxxxxxx xxxxxxxx xx ní xxxxxxxxx. Xxxxx x xxxx dojde, měli xx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxx převzít xxxxxxx, nebylo-li xxxx xxxxxxxx xxxxxxx již xxxxxx, xxxxx xxx xxxxxxx xx xxxxxxxx xxxxxxxx xxxxxxxx, x xxxxxxxx-xx xxxxxxxx xxx xxxxxxxx na xxxx xxxxxxxxxx. |
(12) |
Xxxxx se xxx xxxxxxxxx xxxxxx xxxxx xxxxx, xx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxx přezkumu xxxxxx neodpovídá xxxxxxxx xxxxxxxx hodnocené látky, x x xxxxxxxxx nelze xxxxxxx xxxxxx xxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxx, xxxx xx xxx možné xxxx xxxxx v průběhu hodnocení xxxxx xxxxxxxxx a povolit xxxxx osobám, aby xxxxxxxx podporu této xxxxxxxxx zařazené xxxxx. |
(13) |
Xxxxxxx xxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx nejsou x době xxxxxxx xxxxxx xxxxxxxx podporovány xxxxxx účastníkem. Totéž xx xxxx xxxxxxxx xxxxxxxxxxxxx, ačkoli podle xx. 4 xxxx. 4 nařízení (XX) x. 528/2012 tyto xxxxxxxxx nelze schválit, xxxxx xxx xxxx xxxxxxxx xxxxxxxxx. U xxxxxxxxx xxxxx x xxxxxxxxxxxxx by měly xxx osoby možnost xxxxxxx účast, protože xxxxx xx xxxx xxxxx x xxxxxxxxxxxxx xxxxxx xxx x xxxxxxxx xxxxxxxx xxxxxxxxx. |
(14) |
Xxx xxxx xxxxxxxxx, že xxxxx xxxxx nezůstane x xxxxxxxx xxxxxxxxxxx ani xx xxx nebude xxxxxxxx, aniž xx xxxxxxxx xxxx vyhodnocena, xxxx by setrvání xxxxx, která xxxxx xxxxxx xxxxxxxxx, x xxxxxxxx xxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx údajů o xx, |
XXXXXXX XXXX XXXXXXXX:
KAPITOLA 1
PŘEDMĚT X XXXXXXXX
Xxxxxx 1
Xxxxxxx
Xxxx xxxxxxxx xxxxxxx pravidla pro xxxxxxxxx pracovního programu xxxxxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx x&xxxx;xxxxxx&xxxx;89 xxxxxxxx (XX) x.&xxxx;528/2012.
Xxxxxx 2
Xxxxxxxx
Xxx xxxxx xxxxxx xxxxxxxx xx xxxxxxx xxxx xxxxxxxx:
x) |
„xxxxxxxxxxx x neschválení“ se xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx podle xx. 9 xxxx. 1 xxxx. x) nařízení (XX) x. 528/2012 xxxx xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx, xxxx kombinaci nezařadit xx xxxxxxx X xxxx XX xxxxxxxx 98/8/ES; |
x) |
„kombinací xxxxx x xxxx xxxxxxxxx zařazenou xx xxxxxxxx xxxxxxxx“ xx xxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxx x xxxxxxx II, která xxxxxxx tyto xxxxxxxx:
|
x) |
„xxxxxxxxxx“ se xxxxxx osoba, xxxxx xxxxxxxxxx žádost x xxxxxxxxx látky x xxxx xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxxx, které xxxxxxxx xxxxxxxxxx podle čl. 17 xxxx. 5 xxxxxx nařízení, xxxx xxxxxx jménem xxxx xxxx žádost xxxx xxxxxxxx předloženo; |
x) |
„xxxxxxxxxx xxxxxxxxxx xxxxxxx“ xx xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, xxxxxx x xxxxxxx x xxxxxxx 81 xxxxxxxx (XX) x. 528/2012. |
XXXXXXXX 2
XXXXXX XXXXXXXXX XXXXXXXXXXX
Xxxxxx 3
Xxxxxx x xxxxxxxxx nebo xxxxxxxx xx xxxxxxx I xxxxxxxx (EU) č. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx x&xxxx;xxxxxxxxx xx xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012 může xxxxx xxxxx xxxxxxxx, x xxxxx xxxxxxxx xxxxx xxxxxxxx x xxxxxx, xx odpovídá xxxxxxxxxx podle xx.&xxxx;17 xxxx.&xxxx;5 xxxxxx xxxxxxxx.
Xxxxx xx xxxxxx xxxx xxxxxxxx xx&xxxx;xxxxxxx I nařízení (XX) x.&xxxx;528/2012, xxxx xx týkat pouze xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 uvedené xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx uvedené v odstavci 1 xx podávají xxxxxxxx xx&xxxx;xxxx let xx xxxxxxxxxx x&xxxx;xxxxxxx x požadavky xxxxx xx.&xxxx;17 odst. 5.
Xxxxxx 4
Xxxxxxx xxxxxxx
1. Agentura xxxxxxxxx xxxxxxxxx o xxxxxxxx xxxxxxxx podle xxxxxxxxxxx xxxxxxxx Xxxxxx (XX) x. 564/2013 (7) x zamítne xxxxxx, xxxxx účastník nezaplatí xxxxxxxx xx xxxxx 30 dnů. O xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x hodnotící xxxxxxxxx xxxxx.
2. Po xxxxxxxx xxxxxxxx splatných xxxxx xxxxxxxxxxx xxxxxxxx (EU) x. 564/2013 xxxxxx xxxxxxxx xxxxxx x xxxxxxxxx x xxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxx xxxxx datum xxxxxxx xxxxxxx x xxxx xxxxxxxxx xxxxxxxxxxxxx kód.
3. Proti xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 1 tohoto xxxxxx xxx xxxxx xxxxxxx xxxxxxxxxx x xxxxxxx x článkem 77 xxxxxxxx (XX) x. 528/2012.
4. Hodnotící xxxxxxxxx xxxxx xxxxxxxxx účastníka x xxxxxxxx xxxxxxxx xxxxx xx. 80 xxxx. 2 xxxxxxxx (XX) x. 528/2012 xx 30 xxx xxxx, co xxxxxxxx xxxxxxx žádost, x xxxxxxx xxxxxx, pokud xxxxxxxx xxxxxxxxx poplatek xx xxxxx 30 xxx. O xxxx xxxxxxxxxxx informuje účastníka x xxxxxxxx.
Xxxxxx 5
Potvrzení xxxxxxx x xxxxxxxxx nebo xxxxxxxx xx kategorie 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012
1. Xxxxx xxxxxxxx přijme xxxxx xx. 4 xxxx. 2 xxxxxx x xxxxxxxxx xxxx zařazení xx xxxxxxxxx 6 přílohy X xxxxxxxx (XX) č. 528/2012, xxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxx s čl. 6 xxxx. 1 a 2 xxxxxxxxx nařízení, a byl xxxxxxxx xxxxxxxx xxxxx xx. 4 xxxx. 4, xxxxxxxxx xxxxxxxxx orgán xxxxxx xxxxxxx xx 30 dnů xx xxxxxxxxx xxxxxxxx.
2. Pokud xxxxxxxxx příslušný orgán xxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx nařízení (ES) x. 1451/2007, xxxxx xx xxxxx xxxxxx xxxxxx xxxx úplná xxxxx xxxxxx 13 xxxxxxxxx xxxxxxxx, xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxxxxx xx 3. xxxxx 2015.
3. X xxxxxxxxx xxxxxxxxx x xxxxxxxxxx 1 x 2 xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx kvality xxx xxxxxxxxxxxx xxxxxxxxxxxx xxxxx xxxx odůvodnění.
4. Xxxxx xxxxxxxxx xxxxxxxxx orgán usoudí, xx xxxxxx xx xxxxxxx, xxxxx účastníkovi, xxxx xxxxxxxxxx xxxxxxxxx xxxx x xxxxxxxxx xxxxxxx xxxxx, x x xxxxxxxxxx xxxxxx xxxxxxxxx xxxxxxx přiměřenou xxxxx. Tato xxxxx xxxxx xxxxxxxxxx 90 xxx.
Xxxxxxxx-xx xxxxxxxxx příslušný xxxxx, xx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx ke xxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx 2, xxxxxxx xxxxxx xx 30 dnů xx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx.
Xxxxxxxx xxxxxxxx požadované xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxxx, hodnotící xxxxxxxxx xxxxx xxxxxx xxxxxxx x informuje x xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxx. V xxxxxx případech xx xxxxx xxxxxxxx xxxxxxxxx x xxxxxxx s čl. 80 xxxx. 1 x 2 xxxxxxxx (XX) x. 528/2012.
Xxx xxxxxxxxx žádosti xxxxxxxxx příslušný xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxxxxx x xxxxx xxxxxxxxx xxxxxx a uvede datum xxxxxx xxxxxxxxx.
Xxxxxx 6
Xxxxxxxxx žádostí
1. Tento xxxxxx xx xxxxxxx, xxxxx platí některá x xxxxxx xxxxxxxx:
x) |
xx-xx xxxxxx xxxxxxxxx xxxxx článku 5; |
x) |
xxxxx xxxxxxxxx příslušný xxxxx xxxxx xxxxxxxxxxx xxxx xxxxxx xxxxx xxxxxx 13 xxxxxxxx (XX) x. 1451/2007, ale dosud xxxxxxxxxxx Xxxxxx zprávu xxxxxxxxxxx xxxxxx podle xx. 14 odst. 4 xxxxxxxxx xxxxxxxx; |
x) |
xxxxx xxxxxxxx přijala xxxxxx x xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4 xxxx 5 xxxxxxx X xxxxxxxx (XX) č. 528/2012 xxxxx xx. 4 odst. 2 a xxx zaplacen xxxxxxxx xxxxx xx. 4 xxxx. 4. |
2. Xxxxxxxxx xxxxxxxxx orgán xxxxxxxx xxxxxx podle článků 4 a 5 xxxxxxxx (XX) x. 528/2012 x xxxxxxxx xxx veškeré xxxxxx xx xxxxxx xxxxxxxxx xx xxxxx xxxxxxxxxx x souladu x xx. 6 xxxx. 3 xxxxxxxxx xxxxxxxx x zašle xxxxxxxxx xxxxxx a závěry xxxxx xxxxxxxxx xxxxxxxx.
3. Xxxxx xxxxxxx kombinaci látky x xxxx xxxxxxxxx xxxxxxxxx několik xxxxxxxxx, xxxxxxxxx hodnotící xxxxxxxxx xxxxx xxxxx jednu xxxxxxxxx xxxxxx. Xxxxxxxxx xxxxxx a závěry xxxxx x xxxxx z těchto xxxx, xxxxx xxxx, xx xxxxxxx xxxxxxx:
x) |
365 xxx po xxxxxxxxx xxxxxxxxx uvedeném v odst. 1 xxxx. x), uznání úplnosti xxxxxxxx v odst. 1 xxxx. x) xxxx xxxxxxxxx poplatku xxxxxxxxx x xxxx. 1 xxxx. x) x dotyčné xxxxxxxxx xxxxx a typu přípravku; |
b) |
xx xxxxx xxxxxxxxx x xxxxxxx XXX. |
4. Xxxx xxx, xxx xxxxxxxxx xxxxxxxxx orgán xxxxxxxx xxx xxxxxx xxxxxxxx, xxxxxx xxxxxxxxxxx xxxxx do 30 xxx k xxxxxxxxx xxxxxx x x xxxxxxx xxxxxxxxx písemné xxxxxxxxxx. Xxxxxxxxx příslušný xxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx zohlední x xxxxxxxxx fázi xxxxx xxxxxxxxx.
5. Xxxxx xx xxxxx, xx xxxx x xxxxxxxxx nutné xxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx účastníka xxxxx, xxx xxxx xxxxxxxxx ve stanovené xxxxx xxxxxxxxx, x xxxxxxxxx o xxx xxxxxxxx.
Xxxxx 365 xxx xxxxxxx v odstavci 3 xx xxxxxxx xx xxxx xxx xxx vznesení požadavku xx dne xxxxxxxx xxxxxxxxx. Xxxxx to xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxx xxxxxxxxxx následující xxxxx:
x) |
365 xxx x xxxxxxx, xx xx doplňující xxxxxxxxx xxxxxx xxxxxx, xxxxx xxxxxx xxxxxx x xxxxx xxxxxxxx 98/8/ES xxxx v rámci postupů xxxxxxxxxxx pro xxxxxxxxxxx xxxxxxx xxxxxxxx; |
b) |
180 xxx xx xxxxx xxxxxxxxx případech. |
6. Pokud xxxxxxxxx příslušný xxxxx xxxxxx, xx xxxxxxxx xxxxx ohledně zdraví xxxx nebo xxxxxx xxxx xxxxxxxxx xxxxxxxxx vyplývající x xxxxxxxxxxxxx xxxxxx plynoucích x xxxxxxxxx biocidních xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx účinné xxxxx, xxx xxxxx xxxxxxxxxxxx x xxxxxxx x xxxxxxxxx příslušných xxxxx xxxxxx XX xxxx 3 přílohy XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 1907/2006 (8) x xxxxxx xx xx svých xxxxxx.
7. X xxxxxxx potřeby xx xxxxxxxxx hodnocení xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx bez zbytečného xxxxxxx x xxxxxxxxxx xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxx 3:
x) |
předloží xxxxx agentuře podle xx. 37 xxxx. 1 xxxxxxxx (XX) x. 1272/2008, xxxxxxxx xx domnívá, že je xxxxxxx xxxxx z kritérií xxxxxxxxx x xx. 36 xxxx. 1 xxxxxxxxx xxxxxxxx, xxx xxxx xxxxxxxx xxxxxx x xxxxx 3 přílohy VI xxxxxxxxx xxxxxxxx; |
b) |
konzultuje x xxxxxxxxx, xxxxx se domnívá, xx xxxxx z kritérií xx. 5 xxxx. 1 xxxx. x) xxxx x) xxxxxxxx (EU) x. 528/2012 nebo xxxxxxxx xx. 10 xxxx. 1 xxxx. x) xxxxxxxxx xxxxxxxx xxxx xxxxxxx, ale xxxxxx xxxxxxxx xxxxxx x xxxxxxx XXX nařízení (XX) x. 1907/2006 xxxx x xxxxxxx xxxxxxxx x xx. 59 xxxx. 1 xxxxxxxxx nařízení. |
Xxxxxx 7
Stanovisko agentury
1. Tento xxxxxx se xxxxxxx, xxxxx xxxxx xxxxxxx x xxxxxx podmínek:
x) |
xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxx xxxxx xx. 6 xxxx. 2 x xxxxxxxx xxxxxxxxx xxxxx xxxx xxxxxxx konzultaci xxxxx čl. 6 xxxx. 7; |
b) |
xxxxx xxxx předložena Xxxxxx xxxxxx příslušného orgánu xxxxx čl. 14 xxxx. 4 xxxxxxxx (ES) x. 1451/2007, xxx xxxxxxxxx zprávu xxxxx nepřezkoumal Xxxxx xxxxx xxx xxxxxxxx xxxxxxxxx podle xx. 15 xxxx. 4 uvedeného xxxxxxxx. |
2. Po xxxxxxx xxxxxx xxxxxxxx xxxxxxxxx a předloží Xxxxxx xxxxxxxxxx o schválení xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxx jeho xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxxxxx xxxxxx, s ohledem xx xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx x xxxxx x xxxxxx xxxx, xxxxx xxxx, xx xxxxxxx xxxxxxx:
a) |
xx xxx xxxxxx xx xxxxxxx xxxxxx; |
x) |
ve xxxxx xxxxxxxxx x xxxxxxx XXX. |
Agentura xxxxxxxx xxxxxxxxxx Xxxxxx xx 270 dnů xx xxxxxxxx xxxxxxxx.
Xxxxxx 8
Účinné xxxxx, xxxxx se mají xxxxxxxx
1. Xxx xxxxxxxx xxxxx xxxxxxxxxx podle čl. 7 xxxx. 2 xxxxxxxx prověří, xxx účinná xxxxx xxxxxxx některé z kritérií xxxxxxxxx x xx. 10 xxxx. 1 xxxxxxxx (XX) č. 528/2012, x xxxx xxxxxx xxxxx xx xxxx stanovisku.
2. Xxxx xxxx xxxxxxx xxxxxx 66 x 67 nařízení (XX) x. 528/2012, dříve než xxxxxxxx xxxxxxxx své xxxxxxxxxx Xxxxxx, xxxxxxxx xxxxxxxxx x xxxxxxx látkách, xxxxx xx xxxx xxxxxxxx, během xxxxxxxxx 60 xxx; x xxxx době xxxxx xxxxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx o dostupných xxxxxxxxx. Xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx x xxxxxxxxx fázi xxxxxxxx svého xxxxxxxxxx.
3. Pokud xx xxxxxx xxxxx xxxxxxxxx a splňuje xxxxx x xxxxxxxx xxxxxxxxxxx v čl. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, musí xxx xxxxxxxx za látku, xxxxx xx má xxxxxxxx, x xxxxxxxx xxxxxxxx x xxxxxxx x xx. 89 odst. 1 xxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx 9
Xxxxxxxxxx Xxxxxx
Xx xxxxxxxx xxxxxxxxxx agentury xxxxx xx. 7 xxxx. 2 Xxxxxx xxx xxxxxxxxxx xxxxxxxx připraví xxxxx xxxxxxxxxx xxx xxxxxxx xxxxx xx. 89 odst. 1, xxxx xxxxxxxx xxxxx xx. 28 xxxx. 1 xxxxxxxx (XX) č. 528/2012.
KAPITOLA 3
ZMĚNY XXXXX XXXXXXXX XXXXXXXX
Xxxxxx 10
Xxxxxxxxx xxxx xxxxxxxxx xxxxxxxxx xx vzájemné xxxxxx
1.&xxxx;&xxxx;&xxxx;Xxxx xxxxxxxxx xx xxxxx xx vzájemné xxxxxx xxxx stávajícím xxxxxxxxxx x potenciálním účastníkem xxxxxxx xxxx xxxxxx xx xxxxxxxxxxx, že xx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx se xx xxxxxxx xxxxx xxxxxxxxxx xxxx uvedené xxxxxxxxxx xxxxxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxxx xxx xxxxx xxxxxx článku xxxxxxxxxxx xxxxxxxx společně xxxxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx rejstříku pro xxxxxxxx xxxxxxxxx xxxxxxxxx x článku 71 xxxxxxxx (XX) č. 528/2012 (dále jen „xxxxxxxx“) a oznámení xxxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxx x přístupu.
3. Po xxxxxxxx xxxxxxxx splňujícího xxxxxxxxx xxxxx odstavce 2 xxxxxxxx xxxxxxxxxxx xxxxxxxxx v rejstříku týkající xx totožnosti xxxxxxxxx.
4.&xxxx;&xxxx;&xxxx;Xxxxx xxxxxxx xx&xxxx;xxxxx Xxxx, xxxxx xxxxxxxx xxxx xxxxxxxxx nebo se xxxxxxxxx x xxxxxxxxxxx xxxxx xxxxxx xxxxxx, xx pro účely xxxxxx 95 xxxxxxxx (XX) x.&xxxx;528/2012 považována xx osobu, xxxxx xxxxxxxxxx dokumentaci xxxx xxxxxxxx x xxxxxxxx x xxxxxxxxxxx.
Xxxxxx 11
Odstoupení účastníků
1. Má xx xx xx, xx xxxxxxxx xxxxxxxxx x xxxxxx xx xxxxxxx xxxxxxxxx xxxxx x xxxx přípravku x xxxxxxxx xxxxxxxx, x těchto xxxxxxxxx:
x) |
xxxxx informoval xxxxxxxx xxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x xxxx záměru xxxxxxxxx; |
x) |
xxxxx nepředložil xxxxxx xx xxxxx xxxxxxx x xx. 3 odst. 2; |
c) |
xxxxx jeho xxxxxx xxxx zamítnuta xxxxx čl. 4 xxxx. 1, xx. 4 xxxx. 4 xxxx xx. 5 xxxx. 4; |
x) |
xxxxx xxxxxxxxxxx xxxxxxxxxx informace ve xxxxxxx xxxxxxxxx x xx. 6 xxxx. 5; |
x) |
xxxxx jinak xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx xxxx xxxxxxxx. |
2. Xxxxxxxxxx xx xxxxxxxx xx xxxxxxxxx xxxx, xxxxx x xxxx nedojde xx datu, xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxx xx. 6 odst. 4 xxxxxx xxxxxxxx.
Xxxxxx 12
Xxxxxxxx včasného xxxxxxxxxx
1. Xxxxx je x xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxx xxxxxx agentura, xxxxxxxxx xx xxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxx je o xxxxxxx odstoupení informována xxxxxxxx, xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxxxxx účastníka.
3. Pokud z xxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxx byla xxxx xxxxxxxxx xxx uvedenou xxxxxxxxx dříve převzata, xxxxxxxxx x xxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx Xxxxxx.
Xxxxxx 13
Xxxx xxxxxxxx xxxxxxxxx látek
1. Xxxxx xxxxxxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxx xx xxxxx, xxx jsou xxxxxxx x xxxxxxx XX, xxxxxxxxx xxxxxxxxx xxxxx po xxxxxxxxxx x dotyčným xxxxxxxxxx xxxxxxx xxxxx identitu xxxxx. Xxxxxxxxx příslušný xxxxx x xxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx v rejstříku xxxxxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx.
Xxxxxx 14
Xxxxxxxx role xxxxxxxxx
1. Xxxxxxxx xxxxxxxx otevřenou xxxxx x xxxxxxxx xxxx xxxxxxxxx xxx xxxxxxxxx xxxxx a typu xxxxxxxxx, xxxxx xxxxxxx xxxxx x xxxxxx xxxxxxx:
x) |
pokud xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx látky x xxxx xxxxxxxxx xxxx xxxxxxxxxx xxxxx článku 11 x xxxxxx xxxx xxxxxxxxx xxx xxxxx kombinaci xxxxxx xxxxxxx xxxxxxxx; |
b) |
na základě xxxx definice xxxxx xxxxxx 13; v tomto xxxxxxx xx xxxxx xxxx xxxxx xx xxxxx, xx xxxxxx xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX, xxx xxxxxxx xxxx xxxxxxxx xxxxx. |
2. Do dvanácti xxxxxx xxx xxx zveřejnění xxxxx xxxxxxxx 1 xxxx xxxxxxxxx xxxxx xxxxxxxxx oznámení xxx xxxxxxxxx xxxxx xxxxxx 17.
3. Xx xxxxxxxx xxxxxx xx xxxx xxxxxx tohoto xxxxxxxx x xxxxxxxx může kterákoli xxxxx xxxxxxx kombinaci xxxxx x xxxx xxxxxxxxx xxxxxxxxx xx části 2 xxxxxxx XX xxxxx xxxxxx 17.
Xxxxxx 15
Xxxxxxxxx látky x xxxx xxxxxxxxx xxxxxxxxx pro xxxxxxxx xx xxxxxxxx xxxxxxxx
Xxxxx xxxxxxxx xxxxxxxxx, který xxxxx xx xxxxxxx xxxxxxxxxx nařízení (XX) x. 528/2012 x xx xxxxxx xx trh, xxxxxxx xx stávající xxxxxx xxxxx, jež xxxx xxxxxxxxx xxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxx tento xxx xxxxxxxxx x xxxx xxxxxxxx xx xxxxxxx I xxxxxxxxx xxxxxxxx, tuto xxxxx xxxxxxxx xxxx xx x xx vyrábí, xx uvedená xxxxx xxxxxxxxx xxx xxxxxxxx xx xxxxxxxx přezkumu pro xxxxxxxxx xxx xxxxxxxxx xx xxxxxxx xxxxxxxxx z těchto xxxxxx:
x) |
xxxxx xxxxxxxxx výrobek xx xxx se xxxxxxxxx xx xxxxxx xxxx xxxxxxx doporučení vydané Xxxxxx xxxx xxxxxxxxxx xxxxxxx jmenovaným x xxxxxxx x xxxxxxx 26 xxxxxxxx 98/8/XX xxxx xxxxxxx 81 xxxxxxxx (EU) č. 528/2012, xxxxx xx xxxxxxx xxxxxxxxxx opodstatněných důvodů xxxxx xxxxxxx pokyny xx doporučení x xxxxxxxxxxx, xx xxxxxxx xxx xxxxx x xxxxxxxxxx xxxxxxxx 98/8/XX xxxx xxxxxxxx (XX) x. 528/2012, xxxx xx byl příslušný xxx xxxxxxxxx xxxxxx x xxxxxxxxx, pro xxxxx byla účinná xxxxx xxxxxxxx, x xxxxx jsou uvedené xxxxxx či xxxxxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxxxxx xxxxxxxx xxxxx xx. 3 odst. 3 xxxxxxxx (EU) č. 528/2012 xxxx v nových, xxxxxxxxx xxxxxxxx xxxxxxxxxxxx Xxxxxx; |
x) |
xxxxx xxxxxxxxx odchylky xxx xxxxxxxxx x xxxxxx xxxxxxxxx x xxxxxx 6 xxxxxxxx (XX) x. 1451/2007; |
x) |
xxxxxxxx xxxxxxxxx xxxxx xxxxx nařízení (XX) x. 528/2012 k xxxxxxxxx typu xxxxxxxxx, xxx xxxx xxxx xxxxx směrnice 98/8/ES, v důsledku xxxxx xxxxxxxxxx těchto xxxx xxxxxxxxx x xxxxxxxx xxxxx xxxxxxxxx do programu xxxxxxxx pro xxxxxxx xxx xxxxxxxxx, xxx xxxxxx pro xxxx. |
Xxxxxx 16
Xxxxxxxxxx x xxxxx na oznámení
1. Prohlášení x xxxxx xxxxxxx xxxxx, xxxxx je způsobilá xxx xxxxxxxx do programu xxxxxxxx podle článku 15, xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx kterákoli xxxxx, xxx xx zájem xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, jednomu x xxxxxxxxxxxxx příjemců:
a) |
Xxxxxx xxxxxxxxxx xxxxxxx xxxxxx xx zveřejnění xxxxxxxxxx xxxx xxxxxx xxxxxxxxx x xx. 15 xxxx. x); |
b) |
xxxxxxxx nejpozději 30. xxxxx 2015 x xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x); |
x) |
Xxxxxx xxxxxxxxxx 30. xxxxx 2015 v xxxxxxxxx xxxxxxxxx v čl. 15 xxxx. x). |
2. Xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx. X xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x) musí xxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx odůvodnění, x xxxx xxxxxxx, xx xxxx xxxxxxx xxxxxxx xxxxxxxx x xxx xxxxxxx.
3. Xxxxx bylo xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx v čl. 15 xxxx. x) nebo x) x Xxxxxx xxxxxxx xx xxxxxxxxxx x xxxxxxxxx xxxxx x xxxxxx, xx xxxxxxxx 6 není xxxxxxxxxx, a případně, xx xxxx splněny xxxxxxxx xxx xxxxxxxx uvedené x xx. 15 xxxx. x), xxxxxxx x xxx xxxxxxxx.
4. Xxxxx xxxx prohlášení xxxxxxx v případě xxxxxxxx x xx. 15 xxxx. x) xxxx xxxxx Komise xxxxxxxxxxx agenturu xxxxx xxxxxxxx 3, xxxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx. Xxx xxxxx xxxxxx nařízení xx xxxxxxxxxx xxxxx čl. 3a xxxx. 3 xxxxxxx xxxxxxxxxxx xxxxxxxx (ES) č. 1451/2007 xxxxxxxx za zveřejnění xxxxx tohoto xxxxxxxx.
5. Xxxxxxxxx xxxxx, která xx xxxxx oznámit xxxxxxxxx xxxxx a typu xxxxxxxxx, xxx může xxxxxx xxxxx xxxxxx 17 xx xxxxx xxxxxx xxx dne xxxxxxxxxx xxxxx xxxxxxxx 4.
6. V případech xxxxxxxxx x xx. 15 xxxx. x) a c) xx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxx za xxxxxxxxx účastníkem x xxxx xxxxxxxxx x xxxxxxx xxxxxxxx, xxxxx jsou xxxxxxx tyto podmínky:
x) |
příslušná xxxxxx xxxxx je xxx xxxxxxxx do programu xxxxxxxx; |
x) |
xxxxxxxxxxx předložená xxxxxxxxxxx xxxxxxxxx státu xxx xxxxxxxxxx xxxxxxx xxxxx xxx obsahuje xxxxxxx xxxxx, xxxxx xxxx xxxxxxxx xxx hodnocení xxxx xxxxxxxxx; |
c) |
xxxxxxxx, který xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx, xx xx xxxxx o xxxxxxx xxxx kombinace xxxxx x xxxx xxxxxxxxx. |
Xxxxxx 17
Xxxxxx xxxxxxxx
1. Xxxxxxxx xxxxx xx. 14 xxxx. 2 x 3 xxxx xx. 16 xxxx. 5 xx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxxxxx xxxx xxx xxxxxxxxxx ve xxxxxxx XXXXXX. Musí xxxxxxxxx xxxxx xxxxxxx x xxxxxxx X.
3. Pokud xxxx x xxxxxxx XX xxx xxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxxx jím xxxxxxxxx xxxxxxxxxxx xxxxxx, xxxxx xx xxxxxxxx x xxxxxxx x xxxxxxx 81 nařízení (XX) x. 528/2012, a poskytne xxxxxxx xxxxxxxxx xxxxxxxxxxx, že příslušný xxxxx xxxxxxxx x xxx, xx xxxxxxxxxxx xxxxxxx.
4. Xx obdržení xxxxxxxx x xxx xxxxxxx xxxxxxxx Komisi x xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx podle xxxxxxxx (XX) x. 564/2013. Xxxxxxxx xxxxxxxxxxx xxxxxxxx poplatky xx 30 xxx xx přijetí uvedené xxxxxxxxx, xxxxxxxx oznámení xxxxxxx x xxxxxxx x xxx xxxxxxxxxxxx x Komisi.
5. Po xxxxxxxx xxxxxxxx xxxxxxxx xx 30 dnů ověří, xxx oznámení vyhovuje xxxxxxxxxx xxxxxxxx x xxxxxxxx 2. Xxxxx xxxxxxxx xxxxx požadavkům xxxxxxxxxx, poskytne xxxxxxxx xxxxxxxxxxxx xxxxx v xxxxx 30 xxx, xxx xxx xxxxxxxx xxxxxxx xxxx xxxxxxx. Xx xxxxxxxx xxxx 30xxxxx xxxxx xxxxxxxx xx 30 dnů xxx xxxxxxxx, xx xxxxxxxx xxxxxxxx požadavkům xxxxxxxx 2, xxxx xxxxxxxx xxxxxxx, a xxx xxxxxxxxxx sdělí xxxxxxxxxxxx x Komisi.
6. V xxxxxxx s xxxxxxx 77 xxxxxxxx (EU) x. 528/2012 xxxxx xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 4 xxxx 5 podat xxxxxxx xxxxxxxxxx.
7. Xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx odstavce 5:
x) |
x xxxxxxx, že bylo xxxxxxxx předloženo xxxxx xx. 14 xxxx. 2 xxxx 3, xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxxx x xxxxxxxx identity xxxxx; |
x) |
x xxxxxxx, xx xxxxxxxx xxxx xxxxxxxxxx podle xx. 16 xxxx. 5, agentura xxxxxxxxxx xxxxxxxxx Komisi, xx xxxxxxxxxx xxxx xxxxxxxx. |
Xxxxxx 18
Xxxxxxxx xx xxxxxxxx xxxxxxxx
Xxxxx je xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxxxxxxx xx xxxxxxxxx v souladu s čl. 16 xxxx. 6 nebo xxxxx xxxxxxxx informuje Komisi x xxxxxxxx xxxxxxxxx x souladu s čl. 17 xxxx. 7 xxxx. x), xxxxxx Xxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 19
Xxxxxxxxx x xxxxxxx, které xxxxxx xxxxxx xxxxxxxxxxx v xxxxx xxxxxxxx přezkumu
Xxxxx xxxxxx ve lhůtě xxxxxxxxx x xx. 16 odst. 5 xxxxxxxx xxxxx xxxxxxxx xxxx xxxxx byla oznámení xxxxxxx xx xxxxxxxx xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx agenturou xxxxx xx. 17 odst. 4 xxxx 5, agentura x xxx xxxxxxxxx členské xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxx 20
Xxxxxxxxxx Xxxxxx x xxxxxxx, xxxxx xxxxxx xxxxxx xxxxxxxxxxx x xxxxx programu xxxxxxxx
Xxxxxx připraví xxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxx xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) č. 528/2012 x xxxxxx xxxxxxxxx:
x) |
xxxxx xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxx odstoupení xxxxxxxxx podle xx. 12 xxxx. 3 xxxxxx nařízení; |
x) |
xxxxx xxxxx xxxxx nepodala xxxxxxxx xx xxxxxxx stanovených x xx. 14 odst. 2 xxxx 3 xxxxxx xxxxxxxx xxxx xxxxx bylo xxxxxxxx xxxxxxxxxx a zamítnuto xxxxx xx. 17 odst. 4 xxxx 5; |
x) |
xxxxx bylo xxxxxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx v čl. 14 xxxx. 2 xxxx 3 xxxxxx xxxxxxxx a byly xxxxxxxx xxxxxxxxx xxxxx čl. 17 xxxx. 5 xxxxxx xxxxxxxx, xxx xxxxxxxx látky x xxxxxxxx xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX tohoto xxxxxxxx. |
X xxxxxxx xxxxxxxx x xxxxxx xxxxxxxxxxx xxxx. c) se xxxxx rozhodnutí x xxxxxxxxxxx vztahuje xx xxxxxx látku, na kterou xx xxxxxxxx stávající xxxxxxxx x xxxxxxx XX tohoto xxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxxxx x xxxxxxxxx.
KAPITOLA 4
PŘECHODNÁ XXXXXXXX
Xxxxxx 21
Xxxxxxxxx xxxxxxxx xxx xxxxx xxxxxxx x&xxxx;xxxxxx&xxxx;15
1.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx pokračovat x&xxxx;xxxxxxxxxxx xxxxx stávajícího xxxxxxx xxxx praxe xxxxxxxx xx&xxxx;xxx a používání xxxxxxxxxx přípravku, xxxxx xxxxxxx xx stávající xxxxxx xxxxx xxxxxxx x xx. 15 xxxx. x) x x), tuto xxxxx xxxxxxxx xxxx x xx xxxxxx. V xxxxxx xxxxxxxxx:
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx na trh x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xxxx xxxxxx xxxxxx xxxxxxxx x&xxxx;xxxxxxxx; |
x) |
xxxxxxxxx zásoby xxxxxxxxxx přípravku xxxxx xxx xxxx xxxxxxxxx xx&xxxx;30 xxxxxx po xxx xxxxxx xxxxxx xxxxxxxx x&xxxx;xxxxxxxx. |
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx v uplatňování xxxxx xxxxxxxxxxx systému xxxx xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx biocidního xxxxxxxxx, xxxxx xxxxxxx xx stávající účinné xxxxx uvedené x xx. 15 xxxx. x), xxxx látku xxxxxxxx nebo x xx vzniká. V xxxxxx xxxxxxxxx:
x) |
xxxxx být xxxxxxxx přípravek xxxxxx xxxxxxx na trh x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx po xx x dále xxxxxxxxx událostí, xxxxx xxxxxxx později:
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx dále xxxxxxxxx do 30 měsíců xx xx x xxxx uvedených xxxxxxxx, xxxxx nastane později:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx stát může xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxx dodávání na trh x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx xxxxxx látky xxxxxxxxxx xxxxxxxxx xxxxx xx. 16 xxxx. 4 xxx příslušný xxx xxxxxxx, tuto xxxxx xxxxxxxx nebo x xx vzniká. X xxxxxx případech:
a) |
nesmí xxx biocidní xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx od dvanácti xxxxxx xx xxxx, kdy xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx článku 19 x |
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx dále xxxxxxxxx xx&xxxx;xxxxxxxx xxxxxx po xxxx xxxxxxxxx zveřejnění. |
Xxxxxx 22
Xxxxxxxx xxxxxxx
1. Xxxx xx dotčen čl. 55 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xx xxxxxxxx xxxxxx xx xxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxxx xxxxxx látky, xxxxx xxxxxxx stát xxxxxxxx tuto xxxxxxxxx xxxxxxx xxxxx za xxxxxxxxx x xxxxxx xxxxxxxxx x xx. 5 xxxx. 2 xxxxxx pododstavci xxxx. b) nebo x) xxxxxxxx (XX) x. 528/2012, tento xxxxxxx xxxx může xxxxxxxxx Xxxxxx xxxxxxxxxxx xxxxxx x xxxxxxxx xx xx. 89 odst. 2 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx xxxxxxx xxxx xxxxxxxx odůvodněnou žádost xxxxxxxx xxxxxxxxxxxxxxx rejstříku. Xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxx stát musí xxxxxxx předložit xxxxxxxxx xxxxx.
3. Xxxxxxxx zveřejní xxxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxx xxxxx xxxx xxxx osoby mohou xxxxx xxxxxxxxxx xx xxxxx 60 dnů xx xxxxxxxxxx.
4. Xx xxxxxxx xxxxxxxxxx xxxxxxxxxx může Xxxxxx xxxxxxx xxxxxxxx xx xx. 89 xxxx. 2 druhého xxxxxxxxxxx xxxxxxxx (XX) č. 528/2012, xxxxx xxxxxx xxxxxx xxxxxxxx xxxxxxxxx, xxx xxxxxxxxx x této xxxxx, xxxxxxxx xx xxxx x ní xxxxxxxx, na xxx xxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xx x xxxxx xxxxxxxx xxxxx v souladu x xxxxxxxxxxxxxx právními xxxxxxxx x x xxxxxxxx podmínek xxxxxxxx 5 x xxxxxxxxx xxxxxxx xxxxxxxx uložených Xxxxxx.
5. Xxxxxxx xxxx, xxxxx xx xxxxxxxx odchylka:
a) |
xxxxxxx, xx xxxxx xxxxxxxxx xxxx omezeno xx xxxxxx xxxxxxx x xxxxxxx xxxx, xxx xxxx xxxxxx podmínky xxxxxxxx 1; |
x) |
xxxxxx vhodná opatření xx xxxxxxxx rizik, xxx xxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxx, xxxxxx nebo xxxxxxxxx xxxxxxxxx; |
x) |
xxxxxxx, xxx xx hledala xxxxxxxxxxxx xxxxxx xxxx xxx xxxx včas před xxxxxxxxx platnosti odchylky xxxxxxxxxx žádost o schválení xxxxxx látky x xxxxxxx xxxxxxx 7 nařízení (XX) x. 528/2012. |
XXXXXXXX 5
XXXXXXXXX XXXXXXXXXX
Xxxxxx 23
Xxxxxxx
Xxxxxxx xx nařízení (XX) x. 1451/2007.
Xxxxxx xx zrušené xxxxxxxx xx xxxxxxxx xx xxxxxx na toto xxxxxxxx.
Xxxxxx 24
Vstup x xxxxxxxx
Xxxx xxxxxxxx vstupuje x xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx x Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.
Xxxx xxxxxxxx xx xxxxxxx x xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx všech xxxxxxxxx xxxxxxx.
V Xxxxxxx xxx 4. srpna 2014.
Xx Xxxxxx
xxxxxxxx
José Manuel XXXXXXX
(1)&xxxx;&xxxx;Xx. xxxx. X 167, 27.6.2012, s. 1.
(2)&xxxx;&xxxx;Xxxxxxxx Komise (XX) x. 1451/2007 ze xxx 4. xxxxxxxx 2007 x xxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxx x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx 98/8/XX x xxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx (Xx. věst. X 325, 11.12.2007, x. 3).
(3)&xxxx;&xxxx;Xxxxxxxx Evropského xxxxxxxxxx x Xxxx 98/8/XX xx xxx 16. xxxxx 1998 o xxxxxxx xxxxxxxxxx xxxxxxxxx xx trh (Úř. xxxx. X 123, 24.4.1998, x. 1).
(4)&xxxx;&xxxx;Xxxxxxxx Soudního dvora (xxxxxxx xxxxxx) xx xxx 1. března 2012 (xxxxxx x xxxxxxxxxx o xxxxxxxxx xxxxxx: Landgericht Xxxxxxx – Xxxxxxx) – Xöxx XxxX proti Xxxxx GmbH (uvádění xxxxxxxxxx xxxxxxxxx xx xxx – xxxxxxxx 98/8/XX – xx. 2 xxxx. 1 xxxx. x) – xxxxx „biocidní xxxxxxxxx“ – xxxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxx xx xxxx, xxxxxxxx xxxx xxxxxxxxxxx), C-420/10.
(5) Prováděcí xxxxxxxx Komise (XX) x.&xxxx;88/2014 xx xxx 31.&xxxx;xxxxx 2014, xxxxxx xx stanoví xxxxxx xxx změnu xxxxxxx X&xxxx;xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady (XX) x.&xxxx;528/2012 o dodávání xxxxxxxxxx xxxxxxxxx xx xxx x&xxxx;xxxxxx xxxxxxxxx (Xx. xxxx. X 32, 1.2.2014, x. 3).
(6)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 ze xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx a xxxxxx xxxxx x xxxxx, x xxxxx x xxxxxxx xxxxxxx 67/548/EHS x 1999/45/XX x x xxxxx xxxxxxxx (XX) x. 1907/2006 (Xx. xxxx. L 353, 31.12.2008, s. 1).
(7)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Komise (XX) x.&xxxx;564/2013 xx xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx podle xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx biocidních xxxxxxxxx xx xxx x&xxxx;xxxxxx xxxxxxxxx (Xx.&xxxx;xxxx.&xxxx;X 167, 19.6.2013, s. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 xx xxx 18. prosince 2006 x xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, o xxxxx xxxxxxxx 1999/45/ES x x xxxxxxx nařízení Xxxx (EHS) x.&xxxx;793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX a xxxxxxx Xxxxxx 91/155/EHS, 93/67/XXX, 93/105/XX x 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, x. 1).
XXXXXXX X
Informace požadované xxx xxxxxxxx xxxxx xxxxxx 17
Xxxxxxxx xxxxx xxxxxx 17 xxxxxxxx xxxx xxxxxxxxx:
1) |
xxxxx, že látka xx xxxxxxxxx účinnou xxxxxx xx xxxxxx xx. 3 xxxx. 1 písm. d) xxxxxxxx (XX) x. 528/2012; |
2) |
xxxxx x xxxx/xxxxxx xxxxxxxxx, xx xxxxx/x se xxxxxxxx xxxxxxxx; |
3) |
xxxxxxxxx o všech xxxxxxxx, xxxxx xxxx zadány xxx xxxxx xxxxxxx x xxxxxxxxx xx xxxxxxxx xx xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxx x xxxxxxxxx xxxxx xxxxxx xxxxxxxxx; |
4) |
informace xxxxxxx v xxxxxxxx
|
5) |
pokud xxxx toto oznámení xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 písm. x), xxxxx, xx xxxxx xxxx xx xxxx jako účinná xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxxxxxx x xxx xxxxxxxx xxxx zveřejnění xxxxxxxxxx xxxx xxxxxx xxxxxxxxx xx zmíněném písmenu. |
XXXXXXX II
KOMBINACE XXXXX X XXXX XXXXXXXXX XXXXXXXX XX XXXXXXXX PŘEZKUMU XXX 4. XXXXX 2014
ČÁST 1
Xxxxxxxxx účinné xxxxx x xxxx xxxxxxxxx podporované xx xxx 4. xxxxx 2014, x xxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx xxxx, xxxxx xxxx výslovně xxxxxxx x xxxxxxxxx 1017 a 1019.
Číslo xxxxxxx |
Xxxxx látky |
Členský stát xxxxxxxxx |
Xxxxx ES |
Číslo XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1 |
xxxxxxxxxxx |
DE |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
6 |
5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx xxxxxxxx |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
40 |
propan-2-ol |
XX |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
xxxxxxxx xxxxxxxxxx |
NL |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
xxxxxx-1-xx |
DE |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
N |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
xxxxxxxx xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx xxxxxxxx/2-xxxxxxxxxxxxxxx kyselina |
XX |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
xxxxxxxx xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
71 |
X-(+)-xxxxxx xxxxxxxx |
DE |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-isopropenyl-8,9-dimethoxy-1,2,6,6a,12,12a-hexahydrochromeno[3,4-b]furo[2,3-h]chromen-6-on (xxxxxxx) |
XX |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
85 |
xxxxxxxxx |
UK |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
92 |
xxxxxxx-2-xx |
XX |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
113 |
xxxxxxxxxxxxx/3-xxxxxxxxx-2-xxxx (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx xxxxxxxx (xxxxxxxx xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (xxxxxxxxxxxxx) |
XX |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
154 |
xxxxxxxxx |
X |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-fenoxyethan-1-ol |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
172 |
xxxxxxxxxxxxxxx-xxxxxxx/1-xxxxxxxxxxxxxxxx-1-xxx-xxxxxxx |
UK |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
oxid xxxxxxxx |
XX |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
180 |
(xxxxxxx-xxxxxxxxx) – natrium-dimethylarsinát |
XX |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
185 |
xxxxxxxxxxxxxx, sodná xxx (sodná sůl xxxxxxxxxxxxxxx – chloramin X) – (X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx |
XX |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
xxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
188 |
natrium-dimethyldithiokarbamát |
UK |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
195 |
xxxxxxx-xxxxxxx-2-xxxx |
XX |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
198 |
N-[(trichlormethyl)sulfanyl]ftalimid (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
235 |
diuron |
XX |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
239 |
xxxxxxxxxxxxx |
XX |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
253 |
xxxxxxxxxx-3,5-xxxxxxxx-1,3,5-xxxxxxxxxx-2-xxxxx (dazomet) |
XX |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
279 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X′,X′-xxxxxxxx-X-(4-xxxxxxxxxxx)xxxxxxxxxx (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (dichlofluanid) |
XX |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
289 |
xxxxxxxxxxxx xxxxx |
FR |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
292 |
[(1,3-xxxxx-1,3,4,5,6,7-xxxxxxxxx-2X-xxxxxxxx-2-xx)xxxxxx]-xxxxx-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx xxxxx/xxxxxx xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx xxxxxxxx/xxxxx/xxxxxx vápno/nehašené xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx xxxxx |
XX |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
315 |
butan-2-on-peroxid |
HU |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
xxxxxxxxxxx |
UK |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
N-(3-aminopropyl)-N-dodecylpropan-1,3-diamin (xxxxxx) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
336 |
X,X′-xxxxxxxx-2,2′-xxxxxxxxxxxxxxxxxxxxxx (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (BIT) |
XX |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
341 |
2-methyltetrahydroisothiazol-3(2H)-on (XXX) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
346 |
xxxxxxx-xxxxxxxxxxxxxxxxxx xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (XXX) |
PL |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
triklosan |
XX |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(ethylendioxy)dimethanol (reakční xxxxxxxx xxxxxxxxxxxxxx x xxxxxxxxxxxxxxxx (EGForm)) |
PL |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
365 |
pyridin-2-thiol-1-oxid, xxxxx xxx (xxxxxxxxx sodný) |
XX |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
368 |
1-(3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (XXX) |
XX |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
382 |
1,3,4,6-xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxxxxxxxxx[4,5-x]xxxxxxxx-2,5-xxxx (XXXX) |
XX |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
387 |
xxxxxxxxxxxxxxxxx (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX) |
XX |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
397 |
didecyldimethylamonium-chlorid (XXXX) |
XX |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
401 |
stříbro |
SE |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
403 |
měď |
XX |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
405 |
xxxx xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx sodný |
NL |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
432 |
xxxxxxxx xxxxx |
IT |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
XX |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
439 |
xxxxxxx xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (XXXX) |
PL |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
450 |
xxxxxxxx stříbrný |
SE |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
xxxxxxxxxxxxx xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
IT |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
457 |
xxxxx |
XX |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
458 |
xxxxx xxxxxx |
UK |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
473 |
xxxxxxxxxx x xxxxxxxxxxx |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
491 |
xxxx xxxxxxxxxx |
PT |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
494 |
2,2-dibrom-2-kyanacetamid (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
515 |
xxxxxx xxxxxx |
XX |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
522 |
xxxx-1-xxx-1λ5-xxxxxxx-2-xxxxxxx |
XX |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
524 |
dodecylguanidin-monohydrochlorid |
XX |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
529 |
xxxxxxxxxxxxxxx |
XX |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
531 |
(xxxxxxxxx)xxxxxxxx |
UK |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
534 |
xxx(1-xxxxxxxxxxxxxx-2(1X)-xxxxxxxx-X,X)xxxxxxx komplex (xxxxxxxxx mědi) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
541 |
xxxxxxx-4-xxxxx-3-xxxxxxxxxxxxx |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (CHDG) |
XX |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
559 |
[(xxxxxxxxxxxx-2-xx)xxxxxxxx]xxxxxx-xxxxxxxxxx (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (prallethrin) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
563 |
xxxxxx-(X,X)-xxxx-2,4-xxxxxxx (sorbát xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (XXX) |
XX |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
571 |
2-xxxxxxxxxxxxxxxxxxxxxxxxx-3-xx (OIT) |
UK |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
577 |
dimethyl(oktadecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
XX |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
578 |
X2-xxxx-xxxxx-X4-xxxxxxxxxxx-6-(xxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX/xxxxxxxxxxxxxxxxxxxxxxxxxx) |
NL |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
590 |
3-(4-xxxxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx/xxxxxxxxxxx |
DE |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
597 |
1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]xxxxxxxx (imazalil) |
XX |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
X-[(6-xxxxx-2-xxxxxxxxxx[4,5-x]xxxxxxx-3(2X)-xx)xxxxxx]-X,X-xxxxxxxx-xxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (XXXXX) |
CZ |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
961 |
xxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx vápenato-hořečnatý/hydratované xxxxxxxxxxx xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
608 |
xxxxxxxx(xxxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
PL |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
609 |
xxx- a xxxxx-x-xxxxxxx-3,8-xxxx (xxxx) (xxxxxxxxxx) |
XX |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
614 |
(RS)-α-kyano-3-fenoxybenzyl-(1RS)-cis,trans-3-(2,2-dichlorvinyl)-2,2-dimethylcyklopropanekarboxylát (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
618 |
[1-ethynyl-2-methylpent-2-en-1-yl]-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (xxxxxxxxxx) |
BE |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
619 |
3-jodprop-2-yn-1-yl-N-butylkarbamát (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (THPS) |
XX |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-dichlorfenyl)-4-propyl- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (propikonazol) |
FI |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
635 |
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxx (ATMAC/TMAC) |
XX |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
648 |
4,5-xxxxxxx-2-xxxxxxxxxxxxxxx-3(2X)-xx (4,5-dichlor- 2-xxxxx-2X-xxxxxxxxxx-3-xx (DCOIT)) |
X |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
649 |
1-(2-xxxxxxxxxxx)-3-[(xxxxxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxxxxx) |
XX |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
656 |
bis(5-methyloxazolidin-3-yl)methan (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (cyromazin) |
EL |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
666 |
[(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxx) |
XX |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
667 |
alkyl(C12-18)dimethylbenzylammoniumchlorid (XXXXX (X12-18)) |
XX |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
671 |
xxxxx(X12-16)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX/XXX (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) (X8-10) |
XX |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (XXXXX) |
MT |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
natrium-N-(hydroxymethyl)glycinát |
XX |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
PT |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
bis(peroxosíran)-bis(síran) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx hexahydrát (XXXX) |
XX |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
margosa, Xxxxxxxxxxx xxxxxx, xxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
724 |
alkyl(C12-C14)dimethylbenzylammoniumchlorid (XXXXX (X12-X14)) |
XX |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
725 |
alkyl(C12-C14)ethylbenzylammoniumchlorid (ADEBAC (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
731 |
xxxxxxxxx xxxxxxxxxxxx, Xxxxxxxxxxxxx xxxxxxxxxxxxxxxx, výtažek |
XX |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
744 |
xxxxxxxxx xxxxxx, Xxxxxxxxx xxxxxxx, xxxxxxx/xxxxxxxxxxx xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (hexaflumuron) |
PT |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
779 |
xxxxxxx xxxxxxxx xxxxxxxxx kyseliny a X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (glukoprotamin) |
XX |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-ftalimidoperoxyhexanová kyselina (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (XXXX) |
XX |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
792 |
xxxxxxx xxxxxxxxxxxxxxxxxxx (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
XX |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
794 |
xxx-xxxxx-2,2-(2-xxxxxxxxxxxx)xxxxxxxxx-1-xxxxxxxxxx (xxxxxxxx) |
XX |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
797 |
1-((X)-3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxxxxxxxxx (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx- 1-xxxxxxxxxx (xxxx stereoisomerů) (imiprothrin) |
XX |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
790 |
5-chlor-2-(4-chlorfenoxy)fenol (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (xxxxxxxxxxxxx) |
DE |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
952 |
Xxxxxxxx xxxxxxxxxx 2362, xxxx ABTS-1743 |
XX |
xxxxxxxxxxxxxxx |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx xxxxx. israelensis, xxxx XX3X |
XX |
mikroorganismus |
není xxxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
957 |
Bacillus xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-xxxxx-2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 247-500-7) x 2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 220-239-6), xxxx (3:1) (směs XXXX/XXX) |
XX |
xxxx |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
939 |
aktivní xxxxx (xxxxxxxx reakcí xxxxxxxx xxxxxxx x xxxxxxxxx sodného in xxxx) |
XX |
xxxx |
xxxx relevantní |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
xxxxxxxxxxxxxx kyselina |
XX |
není xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx xxxxxx |
XX |
xxxx relevantní |
xxxx xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
IE |
není relevantní |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
931 |
alkyltrimethylendiaminy, X-X12-14(xx xxxxx xxxxxx), xxxxxxxx reakce x xxxxxxxxxxxx xxxxxxxxx (Xxxxxxxx 20) |
XX |
xxxx xxxxxxxxxx |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
xxxxxxxx xxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxx x chlorem (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
459 |
xxxxxxx xxxx xxxxx titaničitého x xxxxxxxx xxxxxxxxxx |
SE |
není x xxxxxxxxx |
xxxx k dispozici |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
777 |
xxxxxxx xxxxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-ethyl-5-methylhydantoinu x xxxxxxx (XXXXX) |
XX |
xxxx k dispozici |
není k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
810 |
fosforečnanové xxxx x obsahem xxxxxxx |
XX |
xxxx x xxxxxxxxx |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
824 |
xxxxxxxx-xxxxxxxxx xxxxxx |
XX |
xxxx x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx xxxxxx |
XX |
není x xxxxxxxxx |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx xx xxxxx xxxxxxxxxx (xxxx nanomateriál xx xxxxx xxxxxxxxxx xxxxxxxx x primárními xxxxxxxxx xx nanoúrovni) |
SE |
není x xxxxxxxxx |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
1019 |
xxxx xxxxxxxxx (xxxx xxxxxxxxxxxx tvořený xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx x xxxxxxxxx |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
831 |
křemelina |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (směs 4 izomerů 1X xxxxx, 1R: 1X xxxxx, 1S: 1X xxx, 1X: 1X xxx, 1S 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (směs 2 xxxxxxxxxxxxx) (esbiothrin) |
DE |
xxxxxxxxx na xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
835 |
esfenvalerát/(S)-(3-fenoxyfenyl)kyanmethyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-xxxxxxxxxxxx) |
BE |
přípravek xx xxxxxxx xxxxxxx |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (chlorfenapyr) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
859 |
polymer X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) s (xxxxxxxxxxx)xxxxxxxx (EINECS 203-439-8)/polymerní xxxxxxxxx xxxxxxx xxxxxx (XX Xxxxxxx) |
XX |
polymer |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
863 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx) (XXXX) |
XX |
xxxxxxx |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
868 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx-xxxxxxxxxxxx) |
XX |
xxxxxxx |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
869 |
α-[2-(didecylmethylamonio)ethyl]-ω-[hydroxypoly(oxyethylen)-propionát] (Xxxxxx 26) |
XX |
xxxxxxx |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
872 |
X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx-xxxxx/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (xxxxxxxxxxx xxxxxx) |
EL |
xxxxxxx |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
XXXX 2
Xxxxxxxxx xxxxxx látky x xxxx xxxxxxxxx xxxxxxxxxxxxx xx xxx 4. xxxxx 2014
Xxxx xxxx xxxx xxxxxxx xxxxxxxx
— |
kombinace xxxxx a typu xxxxxxxxx xxxxxxx v tabulce xxxx, xxxxxx xxxxxxxxxx xxxxxxxxx, |
— |
xxxxxxxx xxxxxxxxx všech xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx x xxxxxxx x xxxxx 1, xxxxx xxxx, které xxxx xxxxxxx v tabulce, x |
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx účinných xxxxx x xxxx xxxxxxxxx schválených xx 4. xxxxx 2014, x xxxxxxxx těch, které xxxx výslovně xxxxxxxxx. |
Kombinace xxxxx x xxxx xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxx xx této části xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxx xxxxxx 20, jestliže xxxxx xxxxx nepodá xxxxxxxx xx xxxxxxxx xxxxxx xx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx podle xx. 14 xxxx. 3 xxxx xxxxx je xxxxxx xxxxxxxx xxxxxxxxx xxxxx xx. 17 odst. 4 xxxx 5.
Xxxxx xxxxxxx |
Xxxxx xxxxx |
Xxxxxxx xxxx xxxxxxxxx |
Xxxxx ES |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (xxxx definovaný xxxxx xxxxxxx 152) |
NL |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
166 |
xxxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
benzyl(dodecyl)dimethylamonium-chlorid (xxx položka 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(thiazol-4-yl)benzimidazol (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (xxx xxxxxxx 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (viz xxxxxxx 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (xxx xxxxxxx 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
418 |
xxxx xxxxxxxxx xxxxxxx |
XX |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
449 |
xxxxx xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx xxxxxxxx |
SE |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
554 |
4-[(dijodmethyl)sulfonyl]-1-methylbenzen |
XX |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
xxxxx(xxxxxxxx)xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
xxxxxxxxxxxxxx(xxxxxxx-9-xx-1-xx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
637 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxx položka 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (alkyl odvozen xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (viz xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
dialkyl(dimethyl)amonium-chloridy (xxxxx xxxxxxx od xxxxxxxxxxxxxxx xxxxxxxx kyselin xxxx) (xxx položka 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
xxxxxxx(X6-X12)xxxxxxxxxxxxxxx-xxxxxxxx (xxx položka 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
alkyl(C8-C16)benzyl(dimethyl)amonium-chloridy (xxx xxxxxxx 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
xxxxx(X10-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
PT |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
xxxxxxx(X8-X18)xxxxxxxxxxxxxx-xxxxxxxx (xxx xxxxxxx 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
xxxxxxxxxx-xxx(xxxxxxxxxxxxxxxxx)xxxxxxxx xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx xxxxxxx xxxx xxx x xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxxxxxxxx vodou x xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (xxxx definovaný xxxxx xxxxxxx 777) |
XX |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
778 |
1-(4-chlorfenyl)-4,4-dimethyl-3-[(1H-1,2,4-triazol-1-yl)methyl]pentan-3-ol (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx produkt xxxxxxxx-xxxxxxx, xxxxxxxx-xxxxxxxxx a xxxxxxxx-xxxxxxxxx x xxxxxxxxx xxxxxx (xxxxxxxx) |
XX |
432-790-1 |
xxxx xxxxxxxxxx |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (viz xxxxxxx 948) |
|
xxxx |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -bromidy xxxx -xxxxxx-xxxxxxx) (xxxxxx (X6-X18) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx xxxxxxx loje, xxxxxxxxxx xxxxx x xxxxxxxx xxxxx) (DDAC) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
950 |
xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx nebo -methyl-sulfáty) (xxxxxx (X8-X18) nasycené x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx kyselin xxxx, xxxxxxxxxx xxxxx x xxxxxxxx oleje) (XXXX) |
XX |
xxxx xxxxx uvedených x xxxxxxx EINECS |
není xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx nebo -xxxxxxxxx) (alkyly (X8-X22) xxxxxxxx a nenasycené, xxxxxxxx od mastných xxxxxxx xxxx, xxxxxxxxxx xxxxx x xxxxxxxx oleje) (XXX) |
XX |
xxxx xxxxx xxxxxxxxx x seznamu XXXXXX |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (d-fenothrin) |
XX |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
1001 |
xxxxx(X12-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx xxx látka xxxxxxxxx xxx položku 671) |
XX |
xxxx relevantní |
není relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
1002 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx(xxxx xxx xxxxx spadající xxx xxxxxxx 667) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- chloridy (xxxx než látka xxxxxxxxx xxx xxxxxxx 725) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1005 |
alkyl(C12-C14)benzyl(dimethyl)amonium-chloridy (xxxx než xxxxx xxxxxxxxx pod xxxxxxx 724) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1006 |
xxxxxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx, xxxxx, xxxxxx x xxx |
XX |
xxxx xxxxxxxxxx |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1009 |
dialkyl(C8-C10)dimetylamonium-chloridy (jiné xxx xxxxx spadající xxx položku 673) |
IT |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
1011 |
xxxxx(xxxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx od xxxxxxxx xxxxxxx kokosového xxxxx) (xxxx xxx xxxxx xxxxxxxxx xxx položku 635) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1012 |
xxxxxxxxxxxxxxxxx xxxxx, xxxxxxxx x xxxxxxxxx xxxxxxx/xxxxxxxx-xxxxxxxxx zeolit |
XX |
xxxx xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (imazalil xxxxxxxxx) |
XX |
přípravek xx ochranu xxxxxxx |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
Xxxx xxxxxxxxx |
Xxxxx xxx xxxxxxxxxx xxxxxxxxx zprávy xxxxx xx. 6 xxxx. 3 xxxx. x) |
Xxxxx xxx xxxxxxxx xxxxxxxx stanoviska xxxxx xx. 7 xxxx. 2 xxxx. x) |
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
1 a 2 |
31.12.2018 |
31.3.2019 |
6 x 13 |
31.12.2019 |
31.3.2020 |
7, 9 x 10 |
31.12.2020 |
31.3.2021 |
11, 12, 15, 17, 20 x 22 |
31.12.2022 |
31.9.2023 |